immunotherapy

1:36
Crucial role of the cancer nurse in managing patients on CAR T-cell therapy
Kathleen McDermott
2:03
Bispecific antibody response boosting with ibrutinib for CLL
Adrian Wiestner
2:11
Cellular therapies in CLL: from transplant to CAR T-cells?
Jennifer Brown
1:32
Immunotherapeutics against multiple myeloma: it’s all about BCMA
Enrique Ocio
2:39
Vaccines to prevent progression or relapse in multiple myeloma
Ann van de Velde
3:00
CAR T-cells for multiple myeloma: update & what’s in store for ASH 2018
Jesus Berdeja
3:15
Dendritic cell vaccine for MM: Trial updates with maintenance & checkpoint inhibitor pidilizumab
David Avigan
3:43
CAR T-cells for myeloma: an update
Noopur Raje
2:45
Emerging treatments for myeloma: quadruplets, bispecific antibodies & CAR T-cells
Heinz Ludwig
4:24
PVX-410 vaccine for smoldering myeloma
Noopur Raje
2:04
A novel mechanism of action for daratumumab in myeloma
Niels van de Donk
1:20
Investigating vaccines for hem-onc: key questions
David Avigan
1:46
CD38 antibodies under investigation for myeloma: isatuximab, MOR202 & TAK-079
Niels van de Donk
2:49
Daratumumab in myeloma update: expanding indications
Niels van de Donk
2:42
Toxicity profile for CAR T-cells in multiple myeloma
Jesus Berdeja
1:33
CAR T-cell therapy: on the way to success
Steven Rosen
The content of VJHemOnc is intended for healthcare professionals